Literature DB >> 22503123

Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Michael S Dirks1, John A Butman, H Jeffrey Kim, Tianxia Wu, Keaton Morgan, Anne P Tran, Russell R Lonser, Ashok R Asthagiri.   

Abstract

OBJECT: Neurofibromatosis Type 2 (NF2) is a heritable tumor predisposition syndrome that leads to the development of multiple intracranial tumors, including meningiomas and schwannomas. Because the natural history of these tumors has not been determined, their optimal management has not been established. To define the natural history of NF2-associated intracranial tumors and to optimize management strategies, the authors evaluated long-term clinical and radiographic data in patients with NF2.
METHODS: Consecutive NF2 patients with a minimum of 4 years of serial clinical and MRI follow-up were analyzed.
RESULTS: Seventeen patients, 9 males and 8 females, were included in this analysis (mean follow-up 9.5±4.8 years, range 4.0-20.7 years). The mean age at initial evaluation was 33.2±15.5 years (range 12.3-57.6 years). Patients harbored 182 intracranial neoplasms, 164 of which were assessable for growth rate analysis (18 vestibular schwannomas [VSs], 11 nonvestibular cranial nerve [CN] schwannomas, and 135 meningiomas) and 152 of which were assessable for growth pattern analysis (15 VSs, 9 nonvestibular CN schwannomas, and 128 meningiomas). New tumors developed in patients over the course of the imaging follow-up: 66 meningiomas, 2 VSs, and 2 nonvestibular CN schwannomas. Overall, 45 tumors (29.6%) exhibited linear growth, 17 tumors (11.2%) exhibited exponential growth, and 90 tumors (59.2%) displayed a saltatory growth pattern characterized by alternating periods of growth and quiescence (mean quiescent period 2.3±2.1 years, range 0.4-11.7 years). Further, the saltatory pattern was the most frequently identified growth pattern for each tumor type: meningiomas 60.9%, VSs 46.7%, and nonvestibular schwannoma 55.6%. A younger age at the onset of NF2-related symptoms (p=0.01) and female sex (p=0.05) were associated with an increased growth rate in meningiomas. The identification of saltatory growth in meningiomas increased with the duration of follow-up (p=0.01).
CONCLUSIONS: Neurofibromatosis Type 2-associated intracranial tumors most frequently demonstrated a saltatory growth pattern. Because new tumors can develop in NF2 patients over their lifetime and because radiographic progression and symptom formation are unpredictable, resection may be best reserved for symptom-producing tumors. Moreover, establishing the efficacy of nonsurgical therapeutic interventions must be based on long-term follow-up (several years).

Entities:  

Mesh:

Year:  2012        PMID: 22503123      PMCID: PMC4749021          DOI: 10.3171/2012.3.JNS111649

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  38 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

2.  Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment.

Authors:  Joshua M Ammerman; Russell R Lonser; James Dambrosia; John A Butman; Edward H Oldfield
Journal:  J Neurosurg       Date:  2006-08       Impact factor: 5.115

3.  Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease.

Authors:  Ashok R Asthagiri; Gautam U Mehta; Leor Zach; Xiaobai Li; John A Butman; Kevin A Camphausen; Russell R Lonser
Journal:  Neuro Oncol       Date:  2009-12-23       Impact factor: 12.300

4.  Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.

Authors:  David Mathieu; Douglas Kondziolka; John C Flickinger; Ajay Niranjan; Richard Williamson; Juan J Martin; L Dade Lunsford
Journal:  Neurosurgery       Date:  2007-03       Impact factor: 4.654

5.  Radiosurgery for type II neurofibromatosis.

Authors:  Jeremy Rowe; Matthias Radatz; Andras Kemeny
Journal:  Prog Neurol Surg       Date:  2008

6.  Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.

Authors:  Gordon J Harris; Scott R Plotkin; Mia Maccollin; Shubha Bhat; Trinity Urban; Michael H Lev; William H Slattery
Journal:  Neurosurgery       Date:  2008-06       Impact factor: 4.654

7.  Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2.

Authors:  Eiji Ito; Kiyoshi Saito; Hiroshi Yatsuya; Tetsuya Nagatani; Goro Otsuka
Journal:  Neurosurg Rev       Date:  2009-08-12       Impact factor: 3.042

8.  Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Authors:  D Gareth Evans; Marco Giovannini; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; Brigitte Widemann; Kaleb Yohay
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas.

Authors:  Tetsuo Hashiba; Naoya Hashimoto; Shuichi Izumoto; Tsuyoshi Suzuki; Naoki Kagawa; Motohiko Maruno; Amami Kato; Toshiki Yoshimine
Journal:  J Neurosurg       Date:  2009-04       Impact factor: 5.115

10.  Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2.

Authors:  Laurel M Fisher; Joni K Doherty; Michael H Lev; William H Slattery
Journal:  Otol Neurotol       Date:  2007-12       Impact factor: 2.311

View more
  29 in total

1.  Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.

Authors:  Stéphane Goutagny; Eric Raymond; Marina Esposito-Farese; Stéphanie Trunet; Christian Mawrin; Daniele Bernardeschi; Béatrice Larroque; Olivier Sterkers; Marco Giovannini; Michel Kalamarides
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

2.  mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

Authors:  Marco Giovannini; Nicolas-Xavier Bonne; Jeremie Vitte; Fabrice Chareyre; Karo Tanaka; Rocky Adams; Laurel M Fisher; Laurence Valeyrie-Allanore; Pierre Wolkenstein; Stephane Goutagny; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2014-01-10       Impact factor: 12.300

3.  CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.

Authors:  Brigitte C Widemann; Maria T Acosta; Sylvia Ammoun; Allan J Belzberg; Andre Bernards; Jaishri Blakeley; Antony Bretscher; Karen Cichowski; D Wade Clapp; Eva Dombi; Gareth D Evans; Rosalie Ferner; Cristina Fernandez-Valle; Michael J Fisher; Marco Giovannini; David H Gutmann; C Oliver Hanemann; Robert Hennigan; Susan Huson; David Ingram; Joe Kissil; Bruce R Korf; Eric Legius; Roger J Packer; Andrea I McClatchey; Frank McCormick; Kathryn North; Minja Pehrsson; Scott R Plotkin; Vijaya Ramesh; Nancy Ratner; Susann Schirmer; Larry Sherman; Elizabeth Schorry; David Stevenson; Douglas R Stewart; Nicole Ullrich; Annette C Bakker; Helen Morrison
Journal:  Am J Med Genet A       Date:  2014-01-17       Impact factor: 2.802

4.  Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.

Authors:  Alexander Pemov; Ramita Dewan; Nancy F Hansen; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; Kristine Jones; Wen Luo; John D Heiss; James C Mullikin; Prashant Chittiboina; Douglas R Stewart; Ashok R Asthagiri
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

5.  Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.

Authors:  Fu Zhao; Bo Wang; Zhijun Yang; Qiangyi Zhou; Peng Li; Xingchao Wang; Jing Zhang; Junting Zhang; Pinan Liu
Journal:  J Neurooncol       Date:  2018-02-28       Impact factor: 4.130

6.  Comparison of ABC/2 estimation and a volumetric computerized method for measurement of meningiomas using magnetic resonance imaging.

Authors:  Charles F Opalak; Matthew Parry; Andrew K Rock; Adam P Sima; Matthew T Carr; Vyshak Chandra; Kathryn G Workman; Aravind Somasundaram; William C Broaddus
Journal:  J Neurooncol       Date:  2019-08-10       Impact factor: 4.130

7.  Pediatric intracranial lower cranial nerve schwannoma unassociated with neurofibromatosis type 2: case report and review of the literature.

Authors:  Daisuke Hirokawa; Kenichi Usami; Sukwoo Hong; Hideki Ogiwara
Journal:  Childs Nerv Syst       Date:  2019-01-13       Impact factor: 1.475

Review 8.  Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.

Authors:  Jaishri Blakeley
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2012-10       Impact factor: 2.064

9.  Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Filippo G Giancotti; Alexander Filatov; Anna Derman; Tsivia Hochman; Judith D Goldberg; Emilio Vega; Jeffrey H Wisoff; John G Golfinos; Amanda Merkelson; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 10.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.